This clinical context is important as ambroxol crosses the blood–brain barrier and has demonstrated the potential to enhance GCase activity and reduce α-synuclein pathology, supporting its investigation in disease-modifying therapy for GBA1-associated PD. This evidence concerns the gene GBA1 and Parkinson disease.